Explore 3 Stock Ideas & Industry Insights Download Free Report

Company price
0.8766 USD -0.05 ( 5.72%)
Last update at 2026-11-06T21:01:00Z
VOLUME
1097390
Market Cap
152.80M
P/E
2.52

Momentum Score

…

Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, beverages, gummies, and concentrates; and adult use recreational cannabis under the SHRED, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Boxhot, Edison JOLTS, Wola, Rizzlers, DEBUNK, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings and dried flowers to other licensed producers. It sells cannabis products to wholesale and retail channels in the recreational and medical cannabis regimes, as well as through online. Organigram Global Inc. was formerly known as Organigram Holdings Inc. and changed its name to Organigram Global Inc. in March 2025. The company is headquartered in Toronto, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.87
Low
0.94
High
52 Week Price Range
0.85
Low
2.24
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

OrganiGram Holdings Inc is a Canadian licensed cannabis producer that cultivates, processes and sells adult-use and medical cannabis across dried flower, extracts and other derivative formats. Long-term growth could be supported by expansion of Canada's recreational market, product innovation in value-added formats, capacity improvements and selective international opportunities; investors may find the company attractive for its focused product portfolio and potential to benefit from industry consolidation.

Principal risks include regulatory and policy uncertainty, intense domestic competition and pricing pressure, execution and supply-chain challenges, and exposure to financing and market cycles that could constrain growth.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.93
Dividend Yield
-
Revenue TTM
309.18M
Revenue Per Share
2.27
Gross Profit TTM
112.98M
Debt / Equity
0.03
ROE
17.56%
Net Debt
-19.45M
ROCE
-6.34%
Diluted EPS TTM
0.42

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2022-08-31
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2022-08-31
Income before tax -27.66M -45.44M -233.00M -14.37M -14.37M
Net income -17.78M -45.44M -229.48M -14.28M -14.28M
Selling general administrative 55.78M 47.38M 53.82M 42.35M 42.35M
Selling and marketing expenses 31.10M 19.85M 17.86M 16.86M 16.86M
Gross profit 6.83M 47.52M 35.07M 31.57M 31.57M
Reconciled depreciation 17.98M 12.08M - 24.91M 24.91M
Ebit -27.66M -34.76M -48.79M -13.94M -38.75M
Ebitda -14.76M -22.68M -25.37M 10.96M -15.21M
Depreciation and amortization 12.91M 12.08M 23.42M 24.91M 23.54M
Operating income -63.41M -34.76M -242.74M -38.75M -38.75M
Other operating expenses 249.50M 194.60M 391.94M 184.56M 184.56M
Interest expense - - 0.28M 0.43M 0.43M
Tax provision -13.77M 0.00M - -0.09M -0.09M
Net interest income - - - -0.43M -0.43M
Income tax expense -9.89M - -3.52M -0.09M -0.09M
Total revenue 186.09M 159.84M 149.21M 145.81M 145.81M
Total operating expenses 70.24M 82.28M 277.81M 70.32M 70.32M
Cost of revenue 179.26M 112.32M 114.13M 114.24M 114.24M
Total other income expense net 35.74M -10.68M 9.74M 24.38M 24.38M
Net income from continuing ops -24.76M -45.44M - -14.28M -14.28M
Net income applicable to common shares - - -229.48M -14.28M -14.28M
Breakdown 2025-09-30 2024-09-30 2023-09-30 2023-08-31 2022-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2023-08-31 2022-09-30
Total assets 562.21M 407.86M 298.45M 298.45M 577.11M
Intangible assets 48.51M 8.09M 10.62M 10.62M 14.26M
Other current assets 67.06M 34.98M 13.70M 11.00M 8.36M
Total liab 213.08M 101.87M 26.83M 26.83M 69.05M
Total stockholder equity 349.13M 305.99M 271.62M 271.62M 508.06M
Deferred long term liab - - 0.39M 0.39M 0.03M
Other current liab 35.91M 5.14M 1.33M 1.24M 12.00M
Common stock 919.91M 852.89M 776.91M 776.91M 769.73M
Capital stock 919.91M 852.89M - - 769.73M
Retained earnings -608.73M -583.97M -538.53M -538.53M -289.93M
Other liab - - 0.77M 0.77M 11.40M
Good will 52.52M 0.00M - - 41.98M
Other assets - - 0.00M 0.00M 33.14M
Cash 28.20M 106.75M 33.86M 33.86M 68.52M
Total current liabilities 126.16M 53.32M 22.43M 22.43M 55.28M
Current deferred revenue - - 0.09M 0.09M 2.44M
Net debt -19.45M -102.29M -29.14M -29.14M -65.16M
Short term debt 1.00M 1.09M 1.09M 1.09M 1.00M
Short long term debt 0.03M 0.06M - - 0.08M
Short long term debt total 8.75M 4.46M 4.72M 4.72M 3.36M
Other stockholder equity - - 33.24M 33.24M 28.26M
Property plant equipment - - 99.05M 99.05M 259.82M
Total current assets 284.90M 262.22M 155.98M 155.98M 221.62M
Long term investments 49.55M 40.77M - - 7.07M
Net tangible assets - - 261.00M 261.00M 451.82M
Short term investments 0.83M 0.82M - - 30.09M
Net receivables 64.86M 37.15M 27.46M 30.16M 46.37M
Long term debt - 0.03M - - 0.15M
Inventory 123.95M 82.52M 80.95M 80.95M 68.28M
Accounts payable 89.25M 47.10M 20.01M 20.01M 40.86M
Accumulated other comprehensive income 37.95M 37.07M 33.24M 33.24M 28.26M
Non currrent assets other 3.75M 0.59M 19.09M 0.61M 33.14M
Non current assets total 277.31M 145.64M 142.48M 142.48M 355.48M
Capital lease obligations 8.73M 4.37M - - 3.12M
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2022-08-31
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2022-08-31
Investments 1.49M -38.77M 20.15M 95.47M 95.47M
Change to liabilities - - -17.60M 12.15M 12.15M
Total cashflows from investing activities -81.07M -30.80M 1.35M 44.03M 44.03M
Net borrowings -1.85M -0.79M -0.77M -1.01M -1.01M
Total cash from financing activities 39.33M 107.78M -0.81M 5.33M 5.33M
Change to operating activities - - - 1.21M 1.21M
Net income -24.76M -45.44M -229.48M -14.28M -14.28M
Change in cash -49.01M 80.85M -36.87M 13.15M 13.15M
Begin period cash flow 132.60M 51.76M 70.62M 55.37M 55.37M
End period cash flow 83.59M 132.60M 33.86M 68.52M 68.52M
Total cash from operating activities -7.59M 3.87M -35.08M -36.21M -36.21M
Issuance of capital stock 41.18M 108.56M - 0.00M 0.00M
Depreciation 17.98M 12.08M 24.17M 24.91M 24.91M
Other cashflows from investing activities 0.09M -0.35M 28.25M 5.75M 5.78M
Dividends paid - - - 0.00M 0.00M
Change to inventory - - - -12.22M -12.22M
Change to account receivables -15.29M -12.06M 12.51M -37.66M -24.02M
Other cashflows from financing activities -1.29M 0.01M -0.75M -0.09M 6.34M
Change to netincome - - 174.60M -23.96M -23.96M
Capital expenditures 17.05M 5.34M 26.90M 48.78M 48.78M
Change in working capital -2.12M 14.96M 12.51M -22.88M -22.88M
Stock based compensation 4.22M 7.18M 5.29M 5.13M 5.13M
Other non cash items 10.87M 15.09M 152.43M -29.00M -29.00M
Free cash flow -24.64M -1.47M -61.98M -84.99M -84.99M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
OGI
OrganiGram Holdings Inc
-0.05
5.72%
0.88 2.52 14.97 0.49 0.45 0.76 12.75
MKKGY
Merck KGaA ADR
-0.22
0.66%
33.17 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien
-2.76
1.62%
167.12 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR
-0.17
0.80%
21.02 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.
-
-%
41.85 - 10.66 0.01 1.16 2.94 23.11

Profile*

OrganiGram Holdings Inc

Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, beverages, gummies, and concentrates; and adult use recreational cannabis under the SHRED, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Boxhot, Edison JOLTS, Wola, Rizzlers, DEBUNK, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings and dried flowers to other licensed producers. It sells cannabis products to wholesale and retail channels in the recreational and medical cannabis regimes, as well as through online. Organigram Global Inc. was formerly known as Organigram Holdings Inc. and changed its name to Organigram Global Inc. in March 2025. The company is headquartered in Toronto, Canada.

145 King Street West, Toronto, ON, Canada, M5H 1J8

844 644 4726

1139

Name Title Year Born
Ms. Nathalie Batten VP of Operations NA
Mr. Derrick W. West CPA, CPA, (CA) Chief Financial Officer 1967
Ms. Helen Martin Chief Legal Officer & Corp. Sec. 1978
Mr. Gregory Engel Special Advisor 1965
Mr. Timothy Emberg Chief Revenue Officer NA
Mr. Paolo De Luca C.A., C.F.A Chief Strategy Officer 1973
Ms. Beena G. Goldenberg CEO & Director 1963
Mr. Geoff Riggs Chief Information Officer NA
Amy Schwalm VP of Investor Relations NA
Ms. Megan Amber McCrae Sr. VP of Marketing & Communications NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…